Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 17, Issue 12, Pages 1581-1583
Publisher
Informa UK Limited
Online
2016-06-13
DOI
10.1080/14656566.2016.1201073
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers
- (2016) H. J. L. Heerspink et al. DIABETES OBESITY & METABOLISM
- Importance of inhibiting sodium-glucose cotransporter and its compelling indication in type 2 diabetes: pathophysiological hypothesis
- (2016) Genjiro Kimura Journal of the American Society of Hypertension
- Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study
- (2016) Michael A Weber et al. Lancet Diabetes & Endocrinology
- Antihypertensive effects of SGLT2 inhibitors in type 2 diabetes
- (2016) Marcel H A Muskiet et al. Lancet Diabetes & Endocrinology
- Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
- (2015) R. Chilton et al. DIABETES OBESITY & METABOLISM
- Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes
- (2015) William T. Cefalu et al. DIABETOLOGIA
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pleiotropic effects of type 2 diabetes management strategies on renal risk factors
- (2015) Marcel H A Muskiet et al. Lancet Diabetes & Endocrinology
- SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria
- (2014) Yukihiro Chino et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
- (2014) David ZI Cherney et al. Cardiovascular Diabetology
- Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR)
- (2014) Matthew R. Weir et al. CURRENT MEDICAL RESEARCH AND OPINION
- Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
- (2014) Ilkka Tikkanen et al. DIABETES CARE
- Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis
- (2014) A. Liakos et al. DIABETES OBESITY & METABOLISM
- Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis
- (2014) William L. Baker et al. Journal of the American Society of Hypertension
- Dapagliflozin in patients with type 2 diabetes mellitus
- (2014) Theodosios D. Filippatos et al. Therapeutic Advances in Endocrinology and Metabolism
- Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
- (2013) H. J. Lambers Heerspink et al. DIABETES OBESITY & METABOLISM
- Effect of Allopurinol on Blood Pressure of Adolescents With Newly Diagnosed Essential Hypertension
- (2008) Daniel I. Feig et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started